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Recombinant factor VIIa (rFVIIa) can be used for rapid INR normalization in life-threatening hemorrhage in
anticoagulated patients. Dosing is unclear and may carry thromboembolic risks. We reviewed the use of rFVIIa at
a comprehensive stroke and cerebrovascular center to evaluate dose effectiveness on INR reduction and thromboembolic
complications experienced. The primary endpoint was to review the efficacy of rFVIIa in lowering INR. Secondary
endpoints included doses used and adverse effects caused by rFVIIa administration. Forty-one percent of patients
presented with a subdural hemorrhage. The mean INR prior to rFVIIa administration was 3.5 (0.9-15) and
decreased to 1.13 (0.6-2). The mean dose of rFVIIa given was 73 mcg/kg (±24 mcg/kg). Two patients (3%)
experienced a thromboembolic event. Recombinant factor VIIa appears to lower INR without significant
thromboembolic complications.
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Intracranial hemorrhage (ICH) is a potentially devastat-
ing complication of anticoagulation therapy with a mor-
tality rate approaching 50%, twice that of patients not
receiving warfarin therapy (Deveras and Kessler 2002;
Schlunk et al. 2012). Currently, fresh frozen plasma
(FFP) and/or vitamin K are used to reverse warfarin and
normalize the international normalized ratios (INR). Unfor-
tunately, the use of FFP requires large administration vol-
umes and both FFP and vitamin K need significant time for
reversal lending to be problematic in patients with ICH. Ex-
peditious reversal of coagulapathy with a decrease in time
interval to operative intervention may prevent further pro-
gression of the bleed and improve transit time to emer-
gency operative procedures (McQuay et al. 2009).
Recombinant factor VIIa (rFVIIa) has been approved
by the U.S. Food and Drug Administration for the treat-
ment of bleeding in patients with hemophilia A or B
with inhibitors, acquired hemophilia or congenital Fac-
tor VII deficiency. Between 2000 and 2008 the off-label
use of rFVIIa increased by 143-fold (Lin et al. 2012).* Correspondence: nyampolsky@capitalhealth.org
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in any medium, provided the original work is pCurrently, greater than 90% of its use is off-label
(Deveras and Kessler 2002; Yank et al. 2011). It is adminis-
tered at doses that are up to 1000 times the physiologic
level, has a half-life of approximately 2.5 hours, and acts
by increasing the generation of thrombin on thrombin-
activated platelets and through the systemic activation of
coagulation (Levi et al. 2010). rFVIIa comes in a 1 mg/mL
concentration making it very simple to give large doses, if
necessary, in small volumes and in short periods of time.
Its effect is also almost instantaneous, making it a viable
option for administration in order to facilitate procedural
manipulation and possibly reducing the blood loss and
the administration of blood products during a proced-
ure. It has been used off-label to treat bleeding associ-
ated with a variety of conditions including trauma,
surgery, thrombocytopenia, and oral anticoagulant tox-
icity. This has continued despite the boxed warning of
safety concerns with this use.
Although four factor prothrombin complex concen-
trates (PCC) were approved for reversal of warfarin in-
duced coagulopathy in 2013, it is not widely available at
all institutions and in some institutions is more costly
than rFVIIa.
There is unclear evidence for the off-label use of
rFVIIa, specifically for use in intracranial hemorrhageis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 2 Additional agents used for reversal of INR§
Reversal administration n = 58
Received vitamin K only (n, %) 7, 12%
Received FFPΔ only (n, %) 14, 24%
Received both vitamin K and FFP (n, %)) 35, 60%
§international normalized ratio, ΔFresh Frozed Plasma.
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guidelines have not been established. In addition, efficacy
in these settings remains controversial (Freeman et al.
2004; Mayo et al. 2004; Woo et al. 2014). Previous trials
have suggested that rFVIIa for off-label purposes may re-
sult in an increased rate of thromboembolic events (5.1
to 13.8%) with no added benefit for reduction in mortal-
ity rates or improved survival outcomes (Howes et al.
2009; MacLaren et al. 2005; Mayer et al. 2008). The ob-
jectives of this study are to review the usage of recom-
binant factor VIIa for intracranial hemorrhage at a high
volume stroke and cerebrovascular center, evaluate the
effectiveness of the doses used, and report adverse drug
event data in the course of treatment.
Results
Baseline characteristics of the study are shown in Table 1.
A total of 70 patients were identified to have received
rFVIIa between January 1, 2010 and June 30, 2013. Twelve
patients were excluded from data analyses due to present-
ing with a non-neurosurgical reason for needing rFVIIa.
The majority of patients presented with a subdural
hemorrhage (41%) and the average INR prior to rFVIIa
administration was 3.5 (0.9-15). The baseline Glascow
Coma Scale (GCS) for the study was 8.2 (3-15). Forty-
three patients were taking warfarin and one patient was
taking dabigatran.
Forty-nine patients (84%) were emergently taken to the
operating room after rFVIIa administration, of these, 35
patients (60%) received IV vitamin K and fresh frozen
plasma (FFP) in addition to rFVIIa (Table 2). The most
common procedure patients received rFVIIa for was a
hemicraniectomy (51.7%). An external ventricular drainTable 1 Baseline patient characteristics
Patient characteristics n = 58
Mean age (years ± SD) 67.5 ± 16.325
Male (%) 58%
Mean weight (kg ± SD) 82.1 ± 22.4
Anticoagulant at baseline (%) 79%










Mean GCSΔ at baseline (min-max) 8.2 (3-15)
ΔGlascow Coma Scale.
*Other- thoracic epidural hematoma, emergent lumbar puncture, cervical
decompression.was placed in 18.9% of the patients, while 15.5% received
no surgical intervention (Table 3). The mean dose of
rFVIIa given was 73 mcg/kg (±24 mcg/kg) (Table 2). INR
decreased to an average of 1.13 (0.6-2) after the first
administration of rFVIIa (p < 0.001). Forty-two patients
(72%) achieved an INR of 1.4 or less after rVIIa adminis-
tration. Two patients (3%) experienced an adverse event of
thromboembolism that could not be ruled out as second-
ary to rFVIIa. Both events were deep vein thrombosis
(DVT). The average troponin after rFVIIa administration
was 0.4173 ng/mL (0.012-10.15) and 4 patients (6.9%) had
an increased troponin of greater than 1 ng/mL. The aver-
age pH of the patients receiving rFVIIa was 7.39 (7.01-
7.56). Seven patients (12%) had a pH of less than or equal
to 7.3. Six of the seven patients (85.7%) died (Table 4).
Twenty five (43%) total patients died during their hospital
admission. Seventeen patients had a cause of death of de-
clining or not improving neurological status, 4 patients
died due to respiratory failure, and 4 patients experienced
a cardiac arrest.
Discussion
Our study showed that recombinant factor VIIa is an ef-
fective agent to reverse INR in patients presenting in need
of a neurosurgical intervention. It also showed that the
INR reversal comes with no significant risk of thrombo-
embolic complications. This conclusion is corroborated by
other studies that have also investigated the safety of
rFVIIa for warfarin patients (Deveras and Kessler 2002;
DeLoughery et al. 2013; H-Y et al. 2012). To our know-
ledge, this is one the largest retrospective reviews looking
specifically at the use of rFVIIa administration for patients
in need of emergent neurosurgical intervention.Table 3 Surgical procedure performed
Procedure n (%)
Hemicraniectomy 30 (51.7)
External ventricular drain 11 (18.9)
No procedure 9 (15.5)
Burrholes 4 (6.9)
Suboccipital craniectomy 1 (1.7)
Lumbar puncture 1 (1.7)
t1-t4 laminectomy 1 (1.7)
c3-c6 decompression 1 (1.7)
Table 4 pH and in-hospital mortality
Alive Dead Hospital mortality
pH > 7.3 (n = 51) 32 19 37.2%
pH ≤ 7.3 (n = 7) 1 6 85.7%
Total (n = 58) 33 25 43%
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been established, but clinical trials have published doses
ranging from 15–90 mcg/kg (Deveras and Kessler 2002).
rFVIIa is known to rapidly normalize INR in warfarin-
associated systemic bleeding but whether such INR
normalization reflects full reversal of coagulopathy re-
mains controversial (H-Y et al. 2012). Twenty percent of
patients in our study received a dose of rFVIIa less than
50 mcg/kg which is considered low dosing of rFVIIa. All
patients in the low dose group achieved INR normalization
of 1.5 or less. Robbins et al. also showed that lower dosing
appeared to be as effective as higher dosing in normalizing
the INR (Robbins et al. 2013).
The efficacy of rFVIIa may vary under different
physiologic conditions. The activity of rFVIIa has been
found to be significantly decreased when pH levels are
less than 7.02. One study indicated that the activity of
rFVIIa decreased by over 90% at a pH of 7.0. Mamtani
et al. found 100% mortality in coagulopathic and se-
verely acidotic patients (pH ≤ 7.02) who had high bleed-
ing rates despite use of rFVIIa (Mamtani et al. 2012).
We chose to report not only severe acidosis, but also
mild acidosis with a pH ≤ 7.3. Even with the inclusion of
patients with only mild acidosis, our mortality rate for
those patients was 85.7% compared to 37.2% of patients
with no acidosis. This further suggests that the efficacy
of rFVIIa could be decreased with increases in acidosis.
Diringer et al. showed that the risk of having an arter-
ial thrombotic event was significantly increased when
doses of greater than 80 mcg/kg were used (Diringer
et al. 2010). While we did not have any arterial thrombo-
embolic events in our study, one patient that was re-
ported with a deep vein thrombosis (DVT) was given a
dose of 100 mcg/kg, whereas the second patient was
given two doses; the first at 10 mcg/kg which was
followed up by a second 58 mcg/kg dose of rVIIa due of
lack of response.
rFVIIa did not appear to enhance the incidence of
troponin increases in neurosurgical patients. All patients
admitted to the Neurosurgical service receive admission
and post-operative evaluation of troponins per protocol
in order to not overlook any cardiac changes the patient
may be experiencing. Four patients had significantly high
troponins greater than 1 ng/mL. Two of the patients were
determined to have increased troponins due to a stress re-
sponse, one was due to sepsis, and the fourth one was
lower than the troponin taken before rFVII administration.Neither of the two patients that experienced a venous
thromboembolism had an increase in their troponins. We,
therefore, could not correlate a higher prevalence of
thromboembolic events secondary to elevated troponins.
An analysis of 35 randomized controlled trials in 4468
subjects administered rFVIIa for off-label indications
demonstrated a small increase in arterial thromboembol-
ism (5.5% versus 3.5%, p = 0.003), but no difference in
venous thromboembolism. Risk factors appear to be ad-
vancing age and increasing dose (Levi et al. 2010). It has
been stated that the risks of thromboembolic events re-
ported in clinical trials may underestimate the true risk
of thromboembolic events with rFVIIa due to the fact
that many randomized clinical trials did not actively
screen for thromboembolic events (Lin et al. 2012). Pa-
tients admitted to the Capital Health Neurosurgical In-
tensive Care Unit are screened every Tuesday and
Thursday for deep vein thrombosis via lower extremity
Doppler studies assuring a high probability of detecting
any thromboembolic event that may have occurred on
patients that received rFVIIa. Additionally, all patients
receive DVT prophylaxis with subcutaneous heparin and
sequential compression devices up on admission to the
ICU. In addition, the DVT rate of 3% in this study is not
significantly different than the rate seen in other neuro-
surgical populations who do not receive rFVIIa (Patel
et al. 2013).
While rFVIIa is known to normalize INR rapidly,
whether such INR normalization reflects full reversal of
coagulapathy remains controversial. Hemostasis in the
operating room is not always correlated to the INR re-
versal, but given the literature reported high mortality
rates of approximately 50% in patients with intracerebral
bleeding, it remains understandable that clinicians may
wish to try potentially helpful intervention despite lack
of evidence (Schlunk et al. 2012; Donovan et al. 2012).
The mortality rate of our study, 44%, suggests that
rFVIIa was only administered to the sickest patients that
needed reversal emergently in order to attempt interven-
tion as soon as possible. Severity of illness was determined
by the attending neurosurgeon by their evaluation of pa-
tients being prone to bleed expansion, location of bleed,
general patient presentation, and potential for deterior-
ation. A high severity of illness has an expected 30 day
mortality of 72-100% (Greenberg 2010).
The use of PCC has gained some popularity for emer-
gent reversal of anticoagulation (Awad and Cocchio
2013), this use is novel and prior to the approval of 4
factor PCC, our emergent anticoagulant reversal agent
was rFVIIa. At our institution, the price for PCC
is $1.27/unit with an average dose of 25–50 units/kg. In
a 70 kg patient, this equates to $2,200-$4,400. The cost
of rFVIIa is $1467/mg with an average dose of 4–6 mg/
patient, or $5,868-$8,802. PCCs have only been available
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are a comprehensive stroke center that receives many
direct transfer patients from the region’s hospitals, we
have come to realize that PCCs are not widely available
at all institutions.
The study had several limitations. Although one of the
larger studies of rVFIIa use for neurosurgical patients,
our overall sample size is small and this limits our power
to detect small effects. This is also a retrospective review
of rFVIIa use with no control group which can cause
systematic biases and potential confounding variables
that do not allow for definitive conclusions. The range
in doses administered was quite wide and was com-
pletely based on the preference of the attending neuro-
surgeon. In addition, in the future, we plan to compare
our results with reversal of INR and outcomes with
rFVIIa versus PCCs and the use with the newer anticoa-
gulation medications.
Conclusion
rFVIIa appears to rapidly and effectly reverse coagulopa-
thy in patients with intracranial hemorrhage who require
neurosurgical intervention without an increase in thrombo-
embolic events.
Methods
This retrospective chart review was performed in ac-
cordance with the ethical standards set by the institu-
tional review board. After obtaining institutional review
board approval, a retrospective chart review was con-
ducted to identify anti-coagulated patients with intracra-
nial hemorrhage that received rFVIIa. Between January
1, 2010 and June 30, 2013, 58 patients were treated with
rVIIa in Capital Health Regional Medical Center and
Capital Health Medical Center – Hopewell for a neuro-
surgical indication. This time frame was selected because
prior to January 2010 neurosurgical services were very
limited at Capital Health. Patients were excluded if they
were younger than 18 years of age or if they needed
rFVIIa for a non-neurosurgical indication. All patients
receiving rFVIIa during the time period were identified
via hospital billing records. A chart review was then con-
ducted on these patients to identify the indication for
rFVIIa. At our institution, rFVIIa is restricted for off-
label use in Neurosurgery and during Massive Transfu-
sion Protocol only.
The primary objective of this study was to review the
efficacy of rFVIIa. Secondary objectives include review-
ing doses used and adverse effects caused by rFVIIa ad-
ministration. Doses of rFVIIa and the administration of
subsequent doses were recorded for all patients and con-
verted to a weight based dose using the patient’s actual
body weight. The effectiveness of doses used was assessed
by the ability of rFVIIa to correct the INR, which wasdetermined by comparing INR after rFVIIa administration
to pre-administration INR using a Wilcoxon signed rank
test. Administration of vitamin K and FFP were collected
for each patient. Adverse drug events were defined as deep
vein thrombosis, pulmonary embolism, bowel or limb is-
chemia, myocardial infarction or ischemic stroke occur-
ring after administration of rFVIIa and throughout the
hospital admission. Progress notes, discharge summaries,
and imaging studies were evaluated to identify adverse
drug events.
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